We report the first randomized study comparing early hospital discharge with standard hospital-based follow-up after high-dose chemotherapy (HDCT) and PBSCT. Patients aged 18-65 years, with an indication of PBSCT for non-leukemic malignant diseases were randomly assigned between two arms. Arm A consisted of early hospital discharge (HDCT during hospitalization, discharge at day 0, home stay with a caregiver, outpatient clinic follow-up). In arm B patients were followed up as inpatients. In total 131 patients were analyzed (66 in arm A and 65 in arm B). Patient characteristics and hematological reconstitution were comparable between the two groups. In arm A, 26 patients were actually discharged early. Patients in group A spent fewer days in hospital (11 vs 12 days, P ¼ 0.006). This strategy resulted in a 6% mean cost reduction per patient when compared with the conventional hospital-based group. The early discharge approach within the French health system, while safe and feasible, is highly dependent on social criteria (caregiver availability and home to hospital distance). It is almost always associated with conventional hospital readmission during the aplasia phase, and limits cost savings when considering the whole population of patients benefiting from HDCT in routine clinical practice.
Introduction
In standard European practice concerning PBSC autologous transplantation, most patients receive high-dose chemotherapy (HDCT), PBSC reinfusion and post-CT neutropenia in hospital-based treatment and follow-up for around 3-4 weeks. Although a reduction in aplasia duration, thanks to the generalized use of PBSC, has brought about significantly reduced length of inpatient stay, conventional hospital-based follow-up remains an important cost driver of auto-SCT. [1] [2] [3] [4] Traditionally, patients stay in the transplant unit for a period of 3-4 weeks during which they receive HDCT and PBSC infusion with aplasia-supportive-care follow-up. Over the past decade, a number of studies have investigated the efficacy, safety and cost advantages of reduced hospitalization for auto-SCT. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] During this time several models of outpatient (home-and clinic-based or daily clinic-based) and early discharge care (with or without planned readmission) have emerged. 18 Studies usually conclude that HDCT is feasible and safe in the outpatient setting, thanks to the use of hematopoietic growth factors and antimicrobial prophylaxis, which lower aplasia related complications. 13 However, the number of studies comparing inpatient and outpatient HDCT is limited and essentially consist of comparing retrospective or prospective patient cohort studies with a historical group or a case control group, respectively. This methodology obviously limits the transferability of results. Renouncing the dogma of daily medical and nursing care, we offered autologous transplantation patients the opportunity to be followed 1-3 times a week after PBSCT, even during aplasia, in a conventional outpatient unit. Patients could stay at home with a family caregiver between visits to the outpatient unit. Readmission only occurred in cases of neutropenic fever or when any complication related to HDCT arose. The aim of this approach was to decrease the patient's total number of both inpatient and outpatient hospital days. We present here a prospective randomized trial addressing the effect of the implementation of an early discharge program without planned readmission after auto-SCT, on the medical outcomes and on the cost of care.
Patients and methods

Study design
This was a multicenter, randomized comparative trial performed between July 2001 and January 2005 in three French cancer hospitals: Institut Paoli-Calmettes Center (Marseilles), Jean Perrin Center (Clermont-Ferrand) and Hopital Edouard Herriot (Lyon). The protocol was approved by the local ethics committee (CCPPRB de Marseille 2). All procedures were performed after written informed consent was obtained from the patients. In January 2005, 158 patients were randomly assigned to early (arm A) or conventional (Arm B) discharge. The study group (group A) consisted of patients scheduled to be discharged on the same day they had PBSC reinfusion (D0), who would then stay at home and be followed 1-3 times a week in a conventional outpatient clinic until hematological recovery. The control group (group B) consisted of inpatients from D0 until hematological recovery. For both groups, the study period extended from D0 until D60.
The primary end point of the study was the total number of days spent in hospital (inpatient and outpatient) during the study period. Secondary end points were other clinical parameters (that is, number of days of fever, infections, hematologic recovery, transfusions) and real costs of both procedures.
Patients and treatments
To be eligible, patients had to be over 18 and under 65, present a hematological malignancy (except acute leukemia) or a solid tumor with an indication of HDCT with PBSC rescue, and without contraindications to HDCT. Conditioning regimens were chosen according to diagnosis and disease status in accordance with standard hospital protocols. PBSC were infused 24-48 h after the completion of chemotherapy according to the standard procedures associated with each of the conditioning regimens.
For patients randomly assigned to group A, it was considered that early hospital discharge would only be really effective if they had an available family caregiver 24 h a day to help monitor body temperature and oral medication when at home, and if they lived within 45 min driving distance to and from the hospital. Patients not meeting these criteria were not discharged, even when randomized to group A, and were followed as inpatients until they reached discharge criteria.
For all patients
All patients received HDCT and stem cell infusion in conventional non-isolated single hospital rooms. Patients received G-CSF 300 mg/day from D2 until they reached an ANC of more than 0.5 Â 10 9 /L (hematological reconstitution). Patients with febrile neutropenia received immediate first-line i.v. antibiotics (in accordance with hospital protocol) after blood cultures and/or a chest radiograph. No patient with fever was authorized to stay at home. No antibacterial prophylaxis was administered. All patients received prophylactic oral valacyclovir 400 mg twice daily from D2 until D9.
In the case of symptomatic anemia and/or minimal mucocutaneous hemorrhagic syndrome patients received RBC and/or platelets transfusion without taking into account the platelet count and/or the Hb level.
Criteria for hospital discharge (from conventional or outpatient clinic follow-up) were: apyrexia without antibiotics for 24 h, and an ANC of more than 0.5 Â 10 9 /L (after ending post transplant G-CSF).
Conventional-group supportive-care follow-up These patients were treated in conventional non-isolated hospital rooms. They received standard care according to the transplantation unit protocol. Criteria for discharge were as above.
Early-discharge-group supportive care In this group, patients were discharged at D0 (within 6-24 h after PBSC reinfusion). Before discharge, the transplantation chief nurse educated patients and caregivers about athome monitoring and the actions to take if hospitalization was needed at any time. Patients were then followed in the outpatient clinic one to three times a week until D60, according to their clinical status. Each visit at the outpatient clinic determined the delay until the next visit (frequencies of hydration or transfusions). If patients had to come to the outpatient unit more than three times a week, they were readmitted. Patients received i.v. hydration with electrolytes and infusion of vitamins as needed at each outpatient visit throughout the whole of the study period. At the end of each visit they returned back home. They received no home nursing care except for daily injections of G-CSF. Outpatients were readmitted for the following reasons: febrile neutropenia (body temperature 438 1C), requiring i.v. narcotics to manage mucositis pain, patient or family inability to cope at home, uncontrolled emesis, diarrhea, nausea or any serious complication (grade 3, WHO).
Cost analysis
Cost analysis was carried out from the hospital point of view. Direct medical costs were estimated by micro-costing, that is, by measuring physical quantities (capital and labor) consumed for each patient and attributing corresponding monetary costs on the basis of average 2005 French prices. Costs (including room-inpatient and outpatient, blood stem cells harvest, drugs, transfusion and laboratory tests) were estimated on the basis of patients' medical records for both groups from harvest until day 60 after auto-SCT. The actual daily cost was calculated on the basis of the PaoliCalmettes Institute's analytical record for the hematology unit and the outpatient clinic.
Sensitivity analyses were performed to assess the effect of changes in the cost per hospital day in the hematology unit used in the study and in the cost per outpatient clinic visit on the total post-graft cost. For the sensitivity analysis, both unit costs were varied from À50 to þ 200%.
Statistical methods
Randomization was performed before conditioning and was stratified according to the type of programmed conditioning regimen (Bu/TBI vs no Bu/TBI).
Statistical analysis included all patients in group A, even those not discharged early (for medical or organizational reasons). In total, 13 patients were excluded after randomization because of protocol violations: 1 was included in the trial twice and 12 others, who had been randomized into group B, were authorized to go home at D0 (mainly breast cancer patients). To counterbalance this dropout from the analysis and to re-equilibrate the two arms, we excluded 13 correspondingly matched patients from the analysis on the basis of their diagnosis and date of randomization.
Patient characteristics, clinical end points and cost factors expressed in physical units were compared using a w 2 -test for categorical data, Student's t-test for normally distributed quantitative variables and the Mann-Whitney nonparametric test for the other quantitative variables (including costs). Overall survival was estimated from the date of transplantation using death (from any cause) as a relevant event, with censored cases defined as those patients alive at past contact. The Kaplan-Meier method and logrank test were used for estimations and univariate analysis. The level of significance was set at Po0.05. Statistical analysis was carried out using SPSS software (SPSS 18, Chicago, IL, USA).
To compare our results with other outpatient auto-SCT studies, we performed a secondary analysis comparing the subgroup who were actually discharged early (Group A1, n ¼ 30) with the conventional inpatient group (Group B).
Results
Post transplant events
A total of 158 patients were randomized in the clinical trial, 27 patients of whom were excluded (see statistical methods section). A large majority of patients (127 out of 131 patients) included came from only one center, the Institut Paoli-Calmettes in Marseille. Three came from the Centre Jean Perrin (Clermont-Ferrand) and one from Hopital Edouard Heriot (Lyon).
A total of 131 patients receiving HDCT and auto-SCT were analyzed in this study, 66 of whom were randomized in group A (early discharge group) and 65 in group B (conventional inpatient care).
Patient characteristics are summarized in Table 1 . Patients in both groups presented no differences in terms of diagnosis, disease stage at the time of the transplantation, conditioning regimen or total CD34 þ cell dose/kg infused.
Two patients died during the study period, both being randomized in group A. The first patient was readmitted 2 days after discharge (early discharge at day 3) for severe mucositis, diagnosed with severe sepsis with pneumonia during the stay and subsequently died on day 30 post-graft. The second patient presented with very early disease progression (day 30 post graft) and subsequently died on day 39 post graft. Two other patients presented with a life-threatening event. The first, in group B, presented with severe sepsis with pneumonia and acute respiratory distress syndrome, which was resolved with antibiotics without mechanical ventilation in an intensive care unit. The other patient, in group A, presented with a seizure after aplasia, associated with acute renal insufficiency in the context of thrombotic microangiopathy. This was resolved after plasmapheresis in an intensive care unit. Figure 1 describes post transplant events. Thirty patients (46%) in the early discharge group were actually discharged at D0-D1. Four patients (13%) were not readmitted before D60. Two patients (7%) were readmitted after their hematological reconstitution, one because of fever and the other because of extreme asthenia. A total of 10 patients (15%) initially scheduled for early discharge could not be discharged at D0-D1 (persistence in nausea and vomiting and/or fever) nor were 26 others (39%). Of these latter Table 1 Patient characteristics
Early discharge (group A, n ¼ 66)
Conventional inpatient (group B, n ¼ 65)
Patients actually discharged early (group A1, n ¼ 30) Randomized study of early discharge after auto-SCT C Faucher et al 22 (33%) had no family caregiver and the remaining 4 (6%) expressed a desire to stay as inpatients. After discharge (from hospital or outpatient clinic), 4 of these 26 (15%) patients were secondarily admitted before D60. Twelve patients (18%) from the conventional inpatient group were also secondarily admitted before D60, after initial discharge. Post transplant events in the study period (D0-D60) for each group are presented in Table 2 . The median number of visits in the outpatient clinic was one for group A, leading to a total number of days in hospital of 11. In group B, patients spent statistically more days in hospital during the study period with a median of 12 days. Platelet transfusion independence and granulocyte reconstitution were comparable. No patient in group A experienced severe sepsis at home. The number of days of fever, G-CSF administration, the number of transfusions (RBC and platelets) and the percentage of positive cultures were all strictly comparable between group A and B. Figure 2 describes post transplant survival. Median survivals were 89 and 80 months for groups A and B (P ¼ 0.931), respectively. Nine years after autologous transplantation, 47% of the patients were still alive in group A and 45% in group B.
A secondary analysis focused on the comparison between the subgroup of patients actually discharged early (group A1, n ¼ 30) and the conventional inpatient group (group B). We observed an increase in terms of the number of hospital days saved arising from the early discharge procedure, with a median of 7 days of inpatient stay and two visits to the outpatient clinic, leading to a total of 9 hospital days (outpatient and inpatient). Neutrophil and platelet recovery, number of days of fever, G-CSF, number of transfusions and percentage of positive cultures remained comparable Randomized study of early discharge after auto-SCT C Faucher et al with the conventional inpatient group as presented in Table 2 .
Cost analysis results
The total costs of each arm of randomization are presented in Table 3 . Our results showed that the early discharge program led to a 20% decrease in the post-auto-SCT hospitalization cost (3862 h for group A vs 4813 h for group B, P ¼ 0.002). This result is mainly because of decreased inpatient costs (3659 h for group A and 4748 h for group B, P ¼ 0.001) not being counterbalanced by increased outpatient costs (a mean of 203 h and 65 h per patients for groups A and B, respectively, Po0.001). The other auto-SCT cost factors remained similar between the two groups. The mean total cost of auto-SCT observed in our analysis was not statistically different between group A (9777 h) and group B (10 436 h).
The secondary analysis focused on the subgroup of patients actually discharged early (group A1) and here results showed that group A1 presented a mean post-auto-SCT hospitalization cost of 2849 h (vs 4813h for group B, Po0.001). The mean total cost of post-graft auto-SCT follow-up was significantly lower for group A1 than for Group B (4831 h vs 6780 h, respectively, Po0.001). Moreover, when adding the pre-graft auto-SCT cost, the total mean cost of the whole auto-SCT procedure was lower for group A1 than for group B (8421 h vs 10 436 h, respectively, Po0.001).
As expected, comparison of the subgroup of conventional inpatient program with the early discharge group for those patients not discharged at D0 (but randomized in arm A) showed similar costs (10 436 h vs 10 907 h, respectively, not statistically different).
Sensitivity analyses (Figure 3) showed that group B remained more costly than both groups A and A1, independently of the cost per hospital day in the hematology unit and the cost per outpatient clinic visit used in the study.
Discussion
During the past decade, several models of outpatient and early discharge care for HDCT have emerged. 
Table 3
Mean (s.d.) total cost per patient from cells harvest days post-graft for each randomization arm (A and B) and for the subgroup of patients actually discharged early (A1)
Cost category
Patients actually discharged early (group A1, n ¼ 30) This study presents the clinical and economic repercussions of the implementation of an early discharge care program after HDCT by means of a randomized control trial. In several of the other studies outpatients were housed in residential facilities located close to the hospital. 9, 11, 16 Instead, in our program, patients were intentionally followed only 1-3 days a week in the outpatient clinics far from hospitals, so as to give them and their caregivers some 'resting' days. A total of 39% of the routine clinical practice patients with an indication for HDCT were not discharged early for social or psychological reasons (no caregiver, living too far or patient desire to stay as an inpatient). This confirms previous studies, which already highlighted that a lack of caregivers may limit the use of outpatient HSCT programs. 7, 9, 13 As no previous study included the patients not discharged in the outpatient arm in their analysis, we could not discuss the comparability of our results. Moreover, the control groups used in previous studies' comparisons were often subject to the following factors: patient's refusal of outpatient follow-up, insurancecompany refusal, the absence of a caregiver, living too far from the hospital and physicians' decisions that their patient should not join the program. Such a selection bias may have resulted in more severely ill patients being enrolled into the inpatient group, which in turn would have prevented the possibility of arriving at precise conclusions on the basis of these retrospective studies.
To try to reach a point of comparison with previously published studies, we carried out a secondary analysis focusing on the comparison between the subgroup of patients actually discharged at D0/D1 and the conventional inpatient group. We observed a benefit of 5 days of conventional inpatient stay for the early discharge group over their inpatient peers, which is in line with studies comparable to ours. 7, 22 Other reports show large differences in the readmission rate (from 8 (ref. 6) to 90% 12 ). Fernandez et al. 6 observed a rate of readmission of 8%, but their early discharged patients were selected on the basis of their ECOG status (ECOGo2). Westermann et al. 22 showed a 70% readmission rate, which is quite comparable to our 86%. Interestingly, time to readmission in our study was usually within the first week (for 87% of patients readmitted) and mainly before hematological reconstitution (for 93%). As Leger et al. 12 wrote, 'this information is important for the patient and the caregiver in that an admission to the hospital should not be viewed as a setback in treatment but as an expected part of the course'.
We also observed a decrease in the number of days of antibiotics use in the outpatient subgroup A1 but not in group B, while a similar rate of infection and number of days of i.v. antibiotics between the group A and group B were observed, which is in-line with other studies. 6, 9, 23 Antibiotics prophylaxis has been used in most other outpatient and early discharge programs. Our results suggest that the lack of prophylaxis did not result in an unacceptable increase in infectious complications for outpatients.
Economic reasons have been put forward to justify the development of outpatient and early discharge programs, and our analysis confirms the cost savings that the hospital may obtain from the corresponding reduced lengths of stay. Although it is difficult to compare costs' analyses between countries, to date all studies agree that outpatient programs lead to cost savings-from 7 to 47%. 6, 9, 11, 14 In our study, shifting from inpatient to early discharge programs created cost savings of 19% when considering the patients actually discharged early. Considering all the patients randomized in the early discharge program, our early discharge program showed a mean cost per patient only 6% inferior to that for the conventional inpatient group, reflecting less attractive savings than those found in other studies. 6, 9, 11 The strength of our results lies in the study's design. Unlike the present study, previously published studies have not been randomized in nature and consequently the resources associated with the treatment of the proportion of patients not willing or not able to be discharged early were not included. 6, 9, 11 Although our study had a multicenter design, the large majority of our population came from the same center. Although this observation could penalize the generalizability of our results, it is attenuated by the fact that post transplant supportive care is well-standardized in France and generally follows the European Bone Marrow Transplant guidelines. Moreover, a sensitivity analysis established that our results were robust to changes in the hospitalization unit cost. Although the patients' treatments were conducted over a span of three and a half years, no major changes in supportive care appeared during the study period. The main potential sources of variation in clinical practice (added to economical repercussions) were the administration rules of growth factors. However, these were specified in the study's protocol.
Our study focused on the hospital's point of view in terms of the implementation of an early discharge program. Of course, the societal point of view that includes non-medical direct costs (for example, transport costs) together with indirect costs (for example, caregiver's loss of productivity) is crucial in order to accurately analyze all the consequences of setting up an early discharge program and will represent the next step in the analysis of our trial. Another crucial point to consider is the patients' and caregivers' points of view. In our randomized trial we Figure 3 Sensitivity analysis of the total cost to variation in hospitalization unit costs. Total cost differences between the two groups were recalculated using several various costs per hospital day in the hematology unit and costs per outpatient clinic visit, ranging from a 50% decrease up to a 200% increase.
collected data about patients' quality of life together with data regarding patients' and caregivers' associated anxiety and satisfaction, the analysis of which will be the object of a future paper. Our study demonstrated that although early discharge after auto-SCT is safe and feasible, it is highly dependent on social criteria (for example, caregiver availability and distance to/from home and hospital) and it almost always leads to conventional inpatient readmission during the aplastic phase and incurs limited cost savings when considering the whole population of patients likely to routinely benefit from auto-SCT. These results should not lead the medical community to limit the development of early discharge programs, but hospital administrations should be aware that auto-SCT cannot become a 'technical support service' available for all patients treated at home and instead would still necessitate a dedicated unit. Future research should focus on the analysis of large prospective early discharge or outpatient programs to identify subgroups of patients with an indication for outpatient programs, thereby benefitting from this innovative approach.
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